Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preclinical enhancement of anti-melanoma T-cell activity with scFv:TRAIL-armed autologous T cells
NL-OMON36999Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2013
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of scFv:TRAIL-armed autologous T cells in melanoma (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: In vitro enhancement of anti-melanoma activity and In vivo increase in treatment efficacy. Started Apr 2013; status: active, not recruiting.
02
Drugs
scFv:TRAIL-armed autologous T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON36999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36999.